Evidence map›Paper›PMID 42298255›Full record

ArticleEJNMMI physics2026

Limitations in diagnostics and quantification of small lesions with low uptake in the clinical context of prostate

Maike E Lindemann, Walter Jentzen, Alina Küper, Pedro Fragoso Costa, Marcel Gratz, Lale Umutlu, James Nagarajah, Stephan G Nekolla, Ivo Rausch, Ken Herrmann and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in EJNMMI physics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Maike E LindemannHigh-Field and Hybrid MR Imaging, University Hospital Essen, University of Duisburg-Essen, Essen, Germany. maike.lindemann@uk-essen.de.ORCID http://orcid.org/0000-0002-7761-775X
Walter JentzenDepartment of Nuclear Medicine, University Hospital Essen, University of Duisburg-Essen, Essen, Germany.
Alina KüperDepartment of Nuclear Medicine, University Hospital Essen, University of Duisburg-Essen, Essen, Germany.
Pedro Fragoso CostaDepartment of Nuclear Medicine, University Hospital Essen, University of Duisburg-Essen, Essen, Germany.
Marcel GratzHigh-Field and Hybrid MR Imaging, University Hospital Essen, University of Duisburg-Essen, Essen, Germany.
Lale UmutluDepartment of Diagnostic and Interventional Radiology and Neuroradiology, University Hospital Essen, University of Duisburg-Essen, Essen, Germany.
James NagarajahDepartment of Radiology and Nuclear Medicine, Radboud University Medical Center, Nijmegen, The Netherlands.
Stephan G NekollaDepartment of Nuclear Medicine, Klinikum Rechts Der Isar, School of Medicine and Health, Technical University of Munich, Munich, Germany.
Ivo RauschQIMP Team, Center for Medical Physics and Biomedical Engineering, Medical University of Vienna, Vienna, Austria.
Ken HerrmannDepartment of Nuclear Medicine, University Hospital Essen, University of Duisburg-Essen, Essen, Germany.
Harald H QuickHigh-Field and Hybrid MR Imaging, University Hospital Essen, University of Duisburg-Essen, Essen, Germany.
David KerstingDepartment of Nuclear Medicine, University Hospital Essen, University of Duisburg-Essen, Essen, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeThe aim of this study was to investigate the limits of diagnostics and therapy planning for patients with prostate cancer using non-time-of-flight

methodsPET/MRI measurements were performed using a small lesion NEMA phantom. PET data were acquired for nine different activity concentrations (AC). Data of a longer single-bed protocol in the pelvis or a shorter whole-body protocol were reconstructed using relative or absolute scatter correction (SC). PET images were analysed considering a ± 25% deviation range between imaged and true AC as acceptable. Thirteen PSMA-PET/MRI patients with primary lesions or lymph node metastasis < 12 mm in the pelvis were included in this study. The presence of the halo artefact was evaluated in six

resultsFor both radiotracers, the 9.7 mm sphere was still visible at 0.16 kBq/mL with emission times > 40 min. The 3.7 mm sphere was only detectable at 22 kBq/mL with emission times > 4 min. All spheres ≥ 6.5 mm provide acceptable quantification at an AC of 1.32 kBq/mL for

conclusionsThe results demonstrated that the detection of lesions in the sub-centimetre range and a reliable quantification of

Indexed as

177Lu-PSMA therapy18F-PSMA PET/MR68Ga-PSMA PET/MRProstate cancerRadionuclide therapy planning

Identifiers

PMID42298255
PMCPMC13287300

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.